Khiron Life Sciences has successfully exported its registered Colombian cannabis strains, in the form of live clones, to Europe. This represents the first shipment of medical cannabis live plant material to Europe from Colombia and is expected to accelerate access to European.
Through its EU-GMP certified supply chain partners in Europe, Khiron plans to introduce branded, cannabis-based medicinal products based on those already distributed by the Company in Colombia and Peru. Over the last year, more than 13,000 written prescriptions for extracts, formulated with Khiron´s registered cannabis strains, have been issued to patients in Latin America. As clinical evidence mounts, safety and efficacy data arising from Khiron's wholly-owned clinics in Latin America is expected to serve as a cornerstone of the Company's European medical education program.
Tejinder Virk, President of Khiron Europe, commented: "Our experience in Colombia and Europe tells us that doctors require solid clinical evidence to feel confident that medical cannabis is the right treatment for their patients. By exporting our Colombian cannabis strains, we will be able to bring our Latin American extracts to European patients, resulting in wider choices for doctors, and safer, more efficacious patient outcomes. Additionally, this import provides an opportunity to accelerate speed to market, optimize our global diversified supply chain and maximize economics."
Khiron's vertically integrated seed-to-patient business model is currently experiencing tremendous growth in Colombia. To date, Khiron medical cannabis products have shown strong evidence as alternative treatments for ailments such as chronic pain, anxiety, insomnia, depression, epilepsy, migraines, and Parkinson's Disease. With the proof of concept now validated in Colombia, the Company plans to build upon its success in new markets.
For more information:
Khiron Life Sciences Corp.